References

medgen

Медицинская генетика

Medical Genetics

2073-7998

Publishing House «Genius Media» LLC

10.1234/XXXX-XXXX-2015-12-3-10

medgen-73

Research Article

НАУЧНЫЕ ОБЗОРЫ

REVIEW

Механизмы повреждающего действия лекарств на плод и значение фармакогенетики для безопасности лекарств у беременных

Mechanisms of fetal adverse drug effects and importance of pharmacogenetics for safe medication use in pregnancy

Загородникова

К. А.

Zagorodnikova

K. A.

ksenia.zagorodnikova@gmail.com

Бурбелло

А. Т.

Burbello

A. T.

noemail@neicon.ru

Покладова

М. В.

Pokladova

M. V.

noemail@neicon.ru

ГБОУ ВПО СЗГМУ им. И.И.Мечникова; Северо-западный медицинский центр безопасности лекарств при беременности и лактацииРоссияNorth-Western State medical university n.a.I.I.Mechnikov; North-western medical center for drug safety in pregnancy and lactationRussian Federation

2015

16062016

1412310

2016

Загородникова К.А., Бурбелло А.Т., Покладова М.В.

Zagorodnikova K.A., Burbello A.T., Pokladova M.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.medgen-journal.ru/jour/article/view/73

В статье описаны предполагаемые механизмы повреждающего действия лекарственных средств на плод и приведены данные о возможной роли генетических особенностей матери и плода в реализации этих воздействий.

The paper presents review of the mechanisms of adverse effects of medications in human fetus, as well as available data illuminating possible role of maternal and fetal genomes in response to adverse drug reactions induced by treatment of pregnancy-related health conditions.

беременностьплодфармакогенетикапобочные эффекты лекарствpregnancyfetuspharmacogeneticsadverse drug reactions

References1

Загородникова К.А., Бурбелло А.Т., Покладова М.В. Безопасность лекарств и фармаконадзор у беременных - от “талидомидовой трагедии” до наших дней // Ремедиум.- 2012.- № 8.- С. 15-22.

Российский статистический ежегодник. 2014: стат.сб. Москва: , 2014.

Adam M. The all-or-none phenomenon revisited // Birth defects research. Part A, Clinical and molecular teratology. - 2012. - Т.94 №8. - С.664-9.

Ahmadimoghaddam D. идр. Synchronized activity of organic cation transporter 3 (Oct3/Slc22a3) and multidrug and toxin extrusion 1 (Mate1/Slc47a1) transporter in transplacental passage of MPP+ in rat. // Toxicological sciences : an official journal of the Society of Toxicology. -2012. -Т. 128. № 2. -С. 471-81.

Ajslev T.A., Sorensen T.I.A., Jess T. Maternal inflammatory bowel disease and offspring body size: a prospective cohort study. // Inflammatory bowel diseases. -2012. -Т. 18. № 4.-С. 709-17.

BliekB.J.B. и др. Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate. // American journal of medical genetics. Part A. -2009. -Т. 149A. № 10. -С. 2088-92.

Botto L.D., Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. // American journal of epidemiology. -2000. -Т. 151. № 9.-С. 862-77.

Candiotti K.A. идр. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? // Anesthesiology. -2005. -Т. 102. № 3. -С. 543-9.

DaudA.N.A. и др. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. // Pharmacogenomics. -2014. -Т. 15. № 7.-С. 1029-41.

Dreier J.W., Andersen A.-M.N., Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. // Pediatrics. -2014. -Т. 133. № 3. -С. e674-88.

Fejzo M.S., MacGibbon K., Mullin P. Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum. // Reproductive toxicology (Elmsford, N.Y.). -2015.

Gabbay-Benziv R. идр. Birth defects in pregestational diabetes: Defect range, glycemic threshold and pathogenesis. // World journal of diabetes. -2015. -Т. 6. № 3. -С. 481-8.

Gelder M.M.H.J. van идр. Teratogenic mechanisms of medical drugs. // Human reproduction update. -Т. 16. № 4. -С. 378-94.

Gordeeva L.A. идр. Association GSTT1, GSTM1 and GSTP1 (Ile105Val) genetic polymorphisms in mothers with risk of congenital malformations in their children in Western Siberia: a case-control study. // Prenatal diagnosis. -2013. -Т. 33. № 11. -С. 1095-101.

Haas D. Pharmacogenetics and individualizing drug treatment during pregnancy // Pharmacogenomics.- 2014. -Т. 15. -С. 69-78.

Haas D.M. идр. A pilot study of the impact of genotype on nifedipine pharmacokinetics when used as a tocolytic. // The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. -2012. -Т. 25. № 4.-С. 419-23.

Haas D.M. идр. The impact of glucocorticoid polymorphisms on markers of neonatal respiratory disease after antenatal betamethasone administration. // American journal of obstetrics and gynecology. -2013.-Т. 208. № 3. -С. 215.e1-6.

HemauerS.J. и др. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. // Biochemical pharmacology. -2010. -Т. 79. № 6. -С. 921-5.

Herbst A.L., Ulfelder H., Poskanzer D.C. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. // The New England journal of medicine. -1971. -Т. 284. № 15. -С. 878-81.

Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. // Pharmacological reviews. -2010. -Т. 62. № 1.-С. 1-96.

Kobayashi D. идр. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. // Drug metabolism and disposition: the biological fate of chemicals. -2005. -Т. 33. № 1. -С. 94-101.

Koepsell H., Endou H. The SLC22 drug transporter family. // Pflügers Archiv : European journal of physiology. -2004. -Т. 447. № 5.-С. 666-76.

Koren G. Pharmacokinetics in pregnancy; clinical significance. // Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologie clinique. -2011. Т. -18. № 3. -С. e523-7.

Koren G., Bozzo P. Cost effectiveness of teratology counseling - the Motherisk experience. // Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologieclinique.- 2014. -Т. 21. № 2. С.- e266-70.

Landau R. идр. Arg16 homozygosity of the beta2-adrenergic receptor improves the outcome after beta2-agonist tocolysis for preterm labor. // Clinical pharmacology and therapeutics. -2005. -Т. 78. № 6. -С. 656-63.

LankasG.R. и др. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. // Reproductive toxicology (Elmsford, N.Y.). -Т. 12. № 4. -С. 457-63.

Larsen W. Human embryology. Philadelphia: Churchill Livingstone. - 2001. -Вып. 3rd editio.

Lehmann A.S. идр. Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study. // BMC pregnancy and childbirth. -2013. -Т. 13. -С. 132.

Linden I.J.M. van der идр. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. // Journal of molecular medicine (Berlin, Germany). -2006. -Т. 84. № 12. -С. 1047-54.

Lupattelli A. идр. Medication use in pregnancy: a cross-sectional, multinational web-based study. // BMJ open. -2014. -Т. 4. № 2. -С. e004365.

Luteijn J., Brown M., Dolk H. Influenza and congenital anomalies: a systematic review and meta-analysis. // Human reproduction. - 2014. - Т. 29 № 4. - С. 809-23.

Madadi P. идр. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. // Clinical pharmacology and therapeutics. -2009. -Т. 85. № 1.-С. 31-5.

Mazor-Dray E. идр. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? // Journal of Maternal-Fetal and Neonatal Medicine. -2009. -Т. 22. № 2. -С. 124-128.

Meyer zuSchwabedissen H.E. идр. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. // Drug metabolism and disposition: the biological fate of chemicals. -2005. -Т. 33. № 7. -С. 896-904.

Ni Z., Mao Q. ATP-binding cassette efflux transporters in human placenta. // Current pharmaceutical biotechnology. -2011.-Т. 12. № 4. -С. 674-85.

Obermann-Borst S.A. идр. General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect. // American journal of obstetrics and gynecology. -2011. -Т. 204. № 3. -С. 236.e1-8.

Oretti C. идр. Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome. // European journal of clinical pharmacology. -2009.-Т. 65. № 5.-С. 483-91.

Parle-McDermott A. идр. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. // European journal of human genetics : EJHG.- 2006. -Т. 14. № 6.-С. 768-72.

Rahi M. идр. Placental transfer of quetiapine in relation to P-glycoprotein activity. // Journal of psychopharmacology (Oxford, England). -2007. -Т. 21. № 7. -С. 751-6.

Rahi M. идр. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. // Human & experimental toxicology. -2008. -Т. 27. № 1.-С. 65-71.

Rawles L.A., Acuna D., Erickson R.P. The role of multiple drug resistance proteins in fetal and/or placental protection against teratogen-induced orofacial clefting. // Molecular reproduction and development. -2007.-Т. 74. № 11.-С. 1483-9.

Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services. // Congenital anomalies. -2011. -Т. 51. № 1.-С. 6-11.

Shapira S., Dolan S. Genetic risks to the mother and the infant: assessment, counseling, and management. // Maternal and child health journal. - 2006. - T.10 №5. - C. S143-6.

Shepard T.H., Lemire R.J. Catalog of teratogenic agents.11th ed. // The John Hopkins University Press, Baltimore. - 2004. - 487 C.

Staud F., Cerveny L., Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. // Journal of drug targeting.- 2012.-Т. 20. № 9.-С. 736-63.

Stevens A. идр. Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. // The Journal of clinical endocrinology and metabolism. -2004.-Т. 89. № 2.-С. 892-7.

Teh L.K., Bertilsson L. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. // Drug metabolism and pharmacokinetics.- 2012.-Т. 27. № 1.-С. 55-67.

Tertti K. идр. Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). // European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. -2011.-Т. 44. № 3.-С. 181-6.

Ugele B. идр. Characterization and identification of steroid sulfate transporters of human placenta. // American journal of physiology. Endocrinology and metabolism. -2003.- Т. 284. № 2.- С. E390-8.

The authors declare that there are no conflicts of interest present.